Good News： 加拿大将本土生产NOVAVAX疫苗
- 主题发起人 安妹妹
- 开始时间
chicago666
资深人士
- 注册
- 2015-09-07
- 消息
- 7,416
- 荣誉分数
- 1,344
- 声望点数
- 223
这款疫苗目前还在第三阶段试验中，有没有效果待定。
关键是对变种病毒的效果貌似不怎么好。
关键是对变种病毒的效果貌似不怎么好。
chicago666
资深人士
- 注册
- 2015-09-07
- 消息
- 7,416
- 荣誉分数
- 1,344
- 声望点数
- 223
Novavax Inc. (NVAX)周四在英国进行的一项后期试验的中期分析中说，其新冠病毒疫苗在保护人们免受病毒感染方面的有效性为89.3%，此时正值一种令人担忧的冠状病毒毒株一直在英国传播之际。
Novavax说，研究中约有62人在接种疫苗或安慰剂后出现新冠病毒症状。在这些人中，六人接种了疫苗，56人接种了安慰剂。在患病患者中，约有一半感染了英国流行的病毒毒株。
然而，在南非进行的另一项中期研究中，该疫苗的效果较差，当地有另一种变种病毒已经蔓延。在南非，Novavax疫苗在研究中对新冠病毒的有效性约为49.4%。初步结果显示，在可获得测序数据的患病受试者中，超过90%的人感染了在南非流行的新变种病毒。
Novavax说，研究中约有62人在接种疫苗或安慰剂后出现新冠病毒症状。在这些人中，六人接种了疫苗，56人接种了安慰剂。在患病患者中，约有一半感染了英国流行的病毒毒株。
然而，在南非进行的另一项中期研究中，该疫苗的效果较差，当地有另一种变种病毒已经蔓延。在南非，Novavax疫苗在研究中对新冠病毒的有效性约为49.4%。初步结果显示，在可获得测序数据的患病受试者中，超过90%的人感染了在南非流行的新变种病毒。
Novavax is 95.6% effective against the original variant of SARS-CoV-2
vaccine efficacy is 86% against UK variant and 60% against South African variant
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7 (85.6%) and B.1.351 (60%), preliminary data from clinical trials show. Interim results have been...
ModemOutlet
CMobile.ca $25 3GB流量手机计划
- 注册
- 2013-10-03
- 消息
- 2,851
- 荣誉分数
- 444
- 声望点数
- 93
Canada inks deal to produce millions of COVID-19 shots domestically
The work on upgrading the NRC facility has continued and it's now expected to be ready to produce COVID-19 shots sometime this year, the prime minister said, with a production capacity of approximately 4,000 litres per month, which is equivalent to approximately two million doses of a vaccine.
When complete, the facility will be able to make viral vector, protein subunit, virus-like particle based vaccine doses, but not mRNA shots like those developed by Pfizer-BioNTech and Moderna. The Novavax product is of the protein subunit variety.
While construction of the site is expected to finish in July, the NRC facility then has to secure GMP approvals from Health Canada, a process that could take months.
Trudeau said once the plant secures certification, production will start "quickly after that" suggesting the facility could be operational as soon as this summer.
But Innovation Minister François-Philippe Champagne later clarified that the earliest possible production start date is likely "at the end of the year."
The work on upgrading the NRC facility has continued and it's now expected to be ready to produce COVID-19 shots sometime this year, the prime minister said, with a production capacity of approximately 4,000 litres per month, which is equivalent to approximately two million doses of a vaccine.
When complete, the facility will be able to make viral vector, protein subunit, virus-like particle based vaccine doses, but not mRNA shots like those developed by Pfizer-BioNTech and Moderna. The Novavax product is of the protein subunit variety.
While construction of the site is expected to finish in July, the NRC facility then has to secure GMP approvals from Health Canada, a process that could take months.
Trudeau said once the plant secures certification, production will start "quickly after that" suggesting the facility could be operational as soon as this summer.
But Innovation Minister François-Philippe Champagne later clarified that the earliest possible production start date is likely "at the end of the year."
- 注册
- 2005-11-23
- 消息
- 30,321
- 荣誉分数
- 7,459
- 声望点数
- 373
Canada signs deal with Novavax to make its COVID-19 vaccine at new Montreal facility
Prime Minister Justin Trudeau announced a tentative deal Tuesday with U.S. vaccine-maker Novavax to produce its product in Canada if the COVID-19 vaccine gets approved for use here.
“This is a major step forward to get vaccines made in Canada, for Canadians,” Trudeau said.
But the agreement isn’t going to ease pressure on the government to get vaccines into Canada, because Novavax first has to get its vaccine approved, the National Research Council has to finish building a new facility in Montreal where the doses will be made, and that facility has to be certified to make the vaccines.
Novavax applied Friday for regulatory approval in Canada but is still finishing its clinical trials and doesn’t expect to have the final data available for that review for a month or two at least. The NRC facility is going up at lightning speed, said Industry Minister Francois-Philippe Champagne, but it won’t be finished until late summer.
READ MORE
Prime Minister Justin Trudeau announced a tentative deal Tuesday with U.S. vaccine-maker Novavax to produce its product in Canada if the COVID-19 vaccine gets approved for use here.
“This is a major step forward to get vaccines made in Canada, for Canadians,” Trudeau said.
But the agreement isn’t going to ease pressure on the government to get vaccines into Canada, because Novavax first has to get its vaccine approved, the National Research Council has to finish building a new facility in Montreal where the doses will be made, and that facility has to be certified to make the vaccines.
Novavax applied Friday for regulatory approval in Canada but is still finishing its clinical trials and doesn’t expect to have the final data available for that review for a month or two at least. The NRC facility is going up at lightning speed, said Industry Minister Francois-Philippe Champagne, but it won’t be finished until late summer.
READ MORE
